Vimta Labs Ltd.
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 42.4%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (₹ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (₹ Crores, last 1 year)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | ₹344.00 Cr | — | ₹67.00 Cr | — | — | 17.7% | 19.0% | 63.4% |
Showing the latest year only. Sign up free for the full history.
Financial Statements
Income statement, balance sheet, and cash flow (₹ Crores, as reported)
Showing the latest year only. Sign up free for the full history.
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 384 |
| Total Expenses | 250 |
| EBIT / Operating Profit | 134 |
| OPM % | 35% |
| Other Income | 11 |
| Finance Costs | 2 |
| Depreciation & Amortisation | 39 |
| Profit Before Tax | 104 |
| Tax % | - |
| Net Profit / PAT | 79 |
| EPS (₹) | 17.67 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Vimta Labs Ltd.this co. | ₹2.45 K Cr | ₹344.00 Cr | 32.90 | 5.88 | 27.10 | 19.0% |
| Sun Pharmaceutical Industries Ltd. | ₹4.15 L Cr | ₹23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | ₹1.71 L Cr | ₹9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | ₹1.33 L Cr | ₹9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | ₹1.17 L Cr | ₹19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | ₹1.05 L Cr | ₹8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | ₹1.00 L Cr | ₹2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | — | ₹3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |